NCT02203604View on ClinicalTrials.gov

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 26, 2014

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions
Recurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma
Interventions
BIOLOGICAL

aldesleukin

Given IV

BIOLOGICAL

ipilimumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (6)

37240

Vanderbilt University Medical Center, Nashville

44195

Cleveland Clinic, Cleveland

60153

Loyola University Medical Center, Maywood

97213

Providence Portland Medical Center, Portland

02215

Beth Israel Deaconess Medical Center, Boston

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

CINJRegulatory
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

lead

CINJRegulatory

OTHER

NCT02203604 - High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter